Aiolos Bio

Healthcare & Life Sciences

Recent Finacing

Series A

Recent Raise

$245M

Aiolos Bio is a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions, with a lead drug candidate, AIO-001, that is a potentially best-in-class TSLP antibody dosed every 6 months.